{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:16:37Z","timestamp":1776687397845,"version":"3.51.2"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Portuguese Science and Technology Foundation","doi-asserted-by":"crossref","award":["M-ERA-NET-0004\/2015-PAIRED"],"award-info":[{"award-number":["M-ERA-NET-0004\/2015-PAIRED"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Science and Technology Foundation","doi-asserted-by":"crossref","award":["UID\/AGR\/04033\/2019 (CITAB)"],"award-info":[{"award-number":["UID\/AGR\/04033\/2019 (CITAB)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00280-019-03860-z","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T15:26:19Z","timestamp":1557588379000},"page":"15-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Uveal melanoma: physiopathology and new in situ-specific therapies"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-6017","authenticated-orcid":false,"given":"E. B.","family":"Souto","sequence":"first","affiliation":[]},{"given":"A.","family":"Zielinska","sequence":"additional","affiliation":[]},{"given":"M.","family":"Luis","sequence":"additional","affiliation":[]},{"given":"C.","family":"Carbone","sequence":"additional","affiliation":[]},{"given":"C.","family":"Martins-Gomes","sequence":"additional","affiliation":[]},{"given":"S. B.","family":"Souto","sequence":"additional","affiliation":[]},{"given":"A. M.","family":"Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,5,11]]},"reference":[{"issue":"1","key":"3860_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ohc.2004.07.002","volume":"18","author":"AD Singh","year":"2005","unstructured":"Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: epidemiologic aspects. Ophthalmol Clin N Am 18(1):75\u201384. \n                    https:\/\/doi.org\/10.1016\/j.ohc.2004.07.002","journal-title":"Ophthalmol Clin N Am"},{"key":"3860_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4521807","author":"MM Stei","year":"2016","unstructured":"Stei MM, Loeffler KU, Holz FG, Herwig MC (2016) Animal models of uveal melanoma: methods, applicability, and limitations. Biomed Res Int. \n                    https:\/\/doi.org\/10.1155\/2016\/4521807","journal-title":"Biomed Res Int"},{"issue":"1","key":"3860_CR3","first-page":"29","volume":"30","author":"ES Blum","year":"2016","unstructured":"Blum ES, Yang J, Komatsubara KM, Carvajal RD (2016) Clinical management of uveal and conjunctival melanoma. Oncology (Williston Park) 30(1):29\u201332 (34\u201343, 48)","journal-title":"Oncology (Williston Park)"},{"key":"3860_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"BA Krantz","year":"2017","unstructured":"Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD (2017) Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 11:279\u2013289. \n                    https:\/\/doi.org\/10.2147\/OPTH.S89591","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3860_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.22608\/apo.201734","volume":"6","author":"M Dogrusoz","year":"2017","unstructured":"Dogrusoz M, Jager MJ, Damato B (2017) Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol (Phila) 6(2):186\u2013196. \n                    https:\/\/doi.org\/10.22608\/apo.201734","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"3860_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL (2017) Uveal melanoma: relatively rare but deadly cancer. Eye (Lond) 31(2):241\u2013257. \n                    https:\/\/doi.org\/10.1038\/eye.2016.275","journal-title":"Eye (Lond)"},{"issue":"5","key":"3860_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/cam4.133","volume":"2","author":"K Buder","year":"2013","unstructured":"Buder K, Gesierich A, Gelbrich G, Goebeler M (2013) Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med 2(5):674\u2013686. \n                    https:\/\/doi.org\/10.1002\/cam4.133","journal-title":"Cancer Med"},{"key":"3860_CR8","first-page":"896","volume-title":"Histology: a text and atlas: with correlated cell and molecular biology","author":"MH Ross","year":"2011","unstructured":"Ross MH, Pawlina W (2011) Eye. In: Histology: a text and atlas: with correlated cell and molecular biology, 6th edn. Wolters Kluwer Health\/Lippincott Williams & Wilkins, Philadelphia, pp 896\u2013919","edition":"6"},{"key":"3860_CR9","volume-title":"Intraocular (uveal) melanoma treatment, PDQ Cancer Information Summaries [Internet]","author":"PDQ Adult Treatment Editorial Board","year":"2018","unstructured":"PDQ Adult Treatment Editorial Board (2018) Intraocular (uveal) melanoma treatment, PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US), Bethesda (MD)"},{"issue":"2","key":"3860_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jnci.2016.02.003","volume":"28","author":"A Kapoor","year":"2016","unstructured":"Kapoor A, Beniwal V, Beniwal S, Mathur H, Kumar HS (2016) Management of uveal tract melanoma: a comprehensive review. J Egypt Natl Cancer Inst 28(2):65\u201372","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"8","key":"3860_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/archopht.121.8.1163","volume":"121","author":"Collaborative Ocular Melanoma Study G","year":"2003","unstructured":"Collaborative Ocular Melanoma Study G (2003) Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no 21. Arch Ophthalmol 121(8):1163\u20131171. \n                    https:\/\/doi.org\/10.1001\/archopht.121.8.1163","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"3860_CR12","doi-asserted-by":"publisher","first-page":"115472","DOI":"10.1371\/journal.pone.0115472","volume":"9","author":"MD Onken","year":"2014","unstructured":"Onken MD, Li J, Cooper JA (2014) Uveal melanoma cells utilize a novel route for transendothelial migration. PLoS One 9(12):115472\u2013115488","journal-title":"PLoS One"},{"issue":"2","key":"3860_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1755-148X.2012.00979.x","volume":"25","author":"JW Harbour","year":"2012","unstructured":"Harbour JW (2012) The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 25(2):171\u2013181","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"3860_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J, Collaborative Ocular Melanoma Study G (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123(12):1639\u20131643. \n                    https:\/\/doi.org\/10.1001\/archopht.123.12.1639","journal-title":"Arch Ophthalmol"},{"key":"3860_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2147\/OPTH.S113623","volume":"10","author":"K Mahendraraj","year":"2016","unstructured":"Mahendraraj K, Lau CS, Lee I, Chamberlain RS (2016) Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973\u20132012). Clin Ophthalmol 10:2113\u20132119. \n                    https:\/\/doi.org\/10.2147\/OPTH.S113623","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"3860_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/atm.2016.05.04","volume":"4","author":"M Oliva","year":"2016","unstructured":"Oliva M, Rullan AJ, Piulats JM (2016) Uveal melanoma as a target for immune-therapy. Ann Transl Med 4(9):172\u2013182","journal-title":"Ann Transl Med"},{"issue":"7","key":"3860_CR17","first-page":"1230","volume":"6","author":"P Jovanovic","year":"2013","unstructured":"Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6(7):1230\u20131244","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"3860_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.20866","volume":"103","author":"CC McLaughlin","year":"2005","unstructured":"McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW (2005) Incidence of noncutaneous melanomas in the U.S. Cancer 103(5):1000\u20131007. \n                    https:\/\/doi.org\/10.1002\/cncr.20866","journal-title":"Cancer"},{"issue":"8","key":"3860_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA (2009) Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 127(8):989\u2013998. \n                    https:\/\/doi.org\/10.1001\/archophthalmol.2009.208","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"3860_CR20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/bjc.2015.269","volume":"113","author":"A-A Nabil","year":"2015","unstructured":"Nabil A-A, Marie S, Marc-Henri S, Nathalie C, Laurence D, Sophie P-N, Olivier L, Sergio R-R (2015) Upcoming translational challenges for uveal melanoma. Br J Cancer 113(9):1249\u20131253","journal-title":"Br J Cancer"},{"issue":"1","key":"3860_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10555-017-9663-3","volume":"36","author":"A Amaro","year":"2017","unstructured":"Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, Pfeffer U (2017) The biology of uveal melanoma. Cancer Metastasis Rev 36(1):109\u2013140. \n                    https:\/\/doi.org\/10.1007\/s10555-017-9663-3","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3860_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/icu.0000000000000366","volume":"28","author":"D Reichstein","year":"2017","unstructured":"Reichstein D (2017) New concepts in the molecular understanding of uveal melanoma. Curr Opin Ophthalmol 28(3):219\u2013227. \n                    https:\/\/doi.org\/10.1097\/icu.0000000000000366","journal-title":"Curr Opin Ophthalmol"},{"issue":"12","key":"3860_CR23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/bjo.85.12.1440","volume":"85","author":"KA Patel","year":"2001","unstructured":"Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K (2001) Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol 85(12):1440\u20131444","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3860_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1158\/1078-0432.CCR-07-1825","volume":"14","author":"JP Ehlers","year":"2008","unstructured":"Ehlers JP, Worley L, Onken MD, Harbour JW (2008) Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res 14(1):115\u2013122. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1825","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3860_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1167\/iovs.02-0159","volume":"44","author":"AG Scholes","year":"2003","unstructured":"Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK (2003) Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 44(3):1008\u20131011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"24","key":"3860_CR26","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","volume":"16","author":"B Damato","year":"2010","unstructured":"Damato B, Dopierala JA, Coupland SE (2010) Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 16(24):6083\u20136092. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2076","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3860_CR27","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1158\/1078-0432.CCR-06-2383","volume":"13","author":"MD Onken","year":"2007","unstructured":"Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW (2007) Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 13(10):2923\u20132927. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2383","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3860_CR28","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.ophtha.2007.06.012","volume":"114","author":"B Damato","year":"2007","unstructured":"Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, Howard P (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114(10):1925\u20131931. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2007.06.012","journal-title":"Ophthalmology"},{"issue":"7","key":"3860_CR29","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1167\/iovs.08-3165","volume":"50","author":"B Damato","year":"2009","unstructured":"Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE (2009) Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 50(7):3048\u20133055. \n                    https:\/\/doi.org\/10.1167\/iovs.08-3165","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3860_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ophtha.2010.05.023","volume":"118","author":"CL Shields","year":"2011","unstructured":"Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, Shields JA (2011) Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 118(2):396\u2013401. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2010.05.023","journal-title":"Ophthalmology"},{"issue":"2","key":"3860_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0301-4738.154367","volume":"63","author":"S Kaliki","year":"2015","unstructured":"Kaliki S, Shields CL, Shields JA (2015) Uveal melanoma: estimating prognosis. Indian J Ophthalmol 63(2):93\u2013102. \n                    https:\/\/doi.org\/10.4103\/0301-4738.154367","journal-title":"Indian J Ophthalmol"},{"issue":"6009","key":"3860_CR32","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410\u20131413","journal-title":"Science"},{"issue":"7229","key":"3860_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","volume":"457","author":"CD Van Raamsdonk","year":"2009","unstructured":"Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O\u2019Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599\u2013602. \n                    https:\/\/doi.org\/10.1038\/nature07586","journal-title":"Nature"},{"issue":"23","key":"3860_CR34","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O\u2019Brien J, Bastian BC (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191\u20132199. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1000584","journal-title":"N Engl J Med"},{"issue":"4","key":"3860_CR35","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1097\/MD.0000000000002336","volume":"95","author":"SP Patel","year":"2016","unstructured":"Patel SP, Kim DW, Lacey CL, Hwu P (2016) GNA11 mutation in a patient with cutaneous origin melanoma: a case report. Medicine (Baltimore) 95(4):2336\u20132340","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"3860_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","volume":"25","author":"F-X Yu","year":"2014","unstructured":"Yu F-X, Luo J, Mo J-S, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W (2014) Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25(6):822\u2013830","journal-title":"Cancer Cell"},{"issue":"2","key":"3860_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/pcmr.12304","volume":"28","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM (2015) Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 28(2):135\u2013147","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"3860_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","volume":"25","author":"X Feng","year":"2014","unstructured":"Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q, Gutkind JS (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25(6):831\u2013845. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2014.04.016","journal-title":"Cancer Cell"},{"issue":"10","key":"3860_CR39","doi-asserted-by":"publisher","first-page":"109699","DOI":"10.1371\/journal.pone.0109699","volume":"9","author":"X Xu","year":"2014","unstructured":"Xu X, Wei WB, Li B, Gao F, Zhang Z, Jonas JB (2014) Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese. PLoS One 9(10):109699\u2013109705","journal-title":"PLoS One"},{"issue":"3","key":"3860_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/ICU.0000000000000051","volume":"25","author":"MG Field","year":"2014","unstructured":"Field MG, Harbour JW (2014) Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol 25(3):234\u2013239","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"3860_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW (2012) Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18(2):408\u2013416. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0946","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3860_CR42","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","volume":"48","author":"MH Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856\u2013859. \n                    https:\/\/doi.org\/10.1136\/jmedgenet-2011-100156","journal-title":"J Med Genet"},{"issue":"10","key":"3860_CR43","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022\u20131025. \n                    https:\/\/doi.org\/10.1038\/ng.912","journal-title":"Nat Genet"},{"issue":"10","key":"3860_CR44","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018\u20131021. \n                    https:\/\/doi.org\/10.1038\/ng.910","journal-title":"Nat Genet"},{"issue":"2","key":"3860_CR45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/PPO.0b013e31824bd256","volume":"18","author":"SE Woodman","year":"2012","unstructured":"Woodman SE (2012) Metastatic uveal melanoma: biology and emerging treatments. Cancer J 18(2):148\u2013152","journal-title":"Cancer J"},{"issue":"7","key":"3860_CR46","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1167\/iovs.09-4801","volume":"51","author":"MH Abdel-Rahman","year":"2010","unstructured":"Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH (2010) MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci 51(7):3333\u20133339. \n                    https:\/\/doi.org\/10.1167\/iovs.09-4801","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3860_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CMR.0b013e328335a916","volume":"20","author":"P Topcu-Yilmaz","year":"2010","unstructured":"Topcu-Yilmaz P, Kiratli H, Saglam A, Soylemezoglu F, Hascelik G (2010) Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res 20(2):126\u2013132. \n                    https:\/\/doi.org\/10.1097\/CMR.0b013e328335a916","journal-title":"Melanoma Res"},{"issue":"6","key":"3860_CR48","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1167\/iovs.07-0819","volume":"49","author":"MA Economou","year":"2008","unstructured":"Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, Girnita L, Axelson M, Seregard S, Larsson O (2008) Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 49(6):2337\u20132342. \n                    https:\/\/doi.org\/10.1167\/iovs.07-0819","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"3860_CR49","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ijc.21086","volume":"116","author":"T Hausler","year":"2005","unstructured":"Hausler T, Stang A, Anastassiou G, Jockel KH, Mrzyk S, Horsthemke B, Lohmann DR, Zeschnigk M (2005) Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer 116(6):909\u2013913. \n                    https:\/\/doi.org\/10.1002\/ijc.21086","journal-title":"Int J Cancer"},{"issue":"7","key":"3860_CR50","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1167\/iovs.04-1460","volume":"46","author":"E Kilic","year":"2005","unstructured":"Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo HB, Luyten GP, de Klein A (2005) Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci 46(7):2253\u20132257. \n                    https:\/\/doi.org\/10.1167\/iovs.04-1460","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"3860_CR51","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-07-5144","volume":"14","author":"MD Onken","year":"2008","unstructured":"Onken MD, Worley LA, Harbour JW (2008) A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res 14(12):3737\u20133745. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5144","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3860_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/107327481602300202","volume":"23","author":"ZM Correa","year":"2016","unstructured":"Correa ZM (2016) Assessing prognosis in uveal melanoma. Cancer Control 23(2):93\u201398","journal-title":"Cancer Control"},{"issue":"6","key":"3860_CR53","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1167\/iovs.11-8697","volume":"53","author":"T van den Bosch","year":"2012","unstructured":"van den Bosch T, van Beek JG, Vaarwater J, Verdijk RM, Naus NC, Paridaens D, de Klein A, Kilic E (2012) Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci 53(6):2668\u20132674. \n                    https:\/\/doi.org\/10.1167\/iovs.11-8697","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"3860_CR54","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-Hitpass L, Hinnebusch AG, Horsthemke B, Lohmann DR, Zeschnigk M (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45(8):933\u2013936. \n                    https:\/\/doi.org\/10.1038\/ng.2674","journal-title":"Nat Genet"},{"issue":"8","key":"3860_CR55","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1167\/iovs.14-14550","volume":"55","author":"KG Ewens","year":"2014","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, Purrazzella J, Shields CL, Ganguly T, Ganguly A (2014) Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci 55(8):5160\u20135167. \n                    https:\/\/doi.org\/10.1167\/iovs.14-14550","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3860_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45(2):133\u2013135. \n                    https:\/\/doi.org\/10.1038\/ng.2523","journal-title":"Nat Genet"},{"issue":"7","key":"3860_CR57","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","volume":"134","author":"CL Decatur","year":"2016","unstructured":"Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW (2016) Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol 134(7):728\u2013733. \n                    https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.0903","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"3860_CR58","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R (2013) SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 3(10):1122\u20131129. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0330","journal-title":"Cancer Discov"},{"issue":"11","key":"3860_CR59","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd3823","volume":"11","author":"S Bonnal","year":"2012","unstructured":"Bonnal S, Vigevani L, Valcarcel J (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11(11):847\u2013859. \n                    https:\/\/doi.org\/10.1038\/nrd3823","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3860_CR60","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ng.3549","volume":"48","author":"AR Moore","year":"2016","unstructured":"Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, Huber T, Chi P, Sakmar TP, Chen Y (2016) Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 48(6):675\u2013680. \n                    https:\/\/doi.org\/10.1038\/ng.3549","journal-title":"Nat Genet"},{"issue":"4","key":"3860_CR61","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.6614","volume":"7","author":"P Johansson","year":"2016","unstructured":"Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, Ingvar C, Vermeulen T, Whitehead KJ, Schmidt CW, Palmer JM, Symmons J, Gerdes AM, Jonsson G, Hayward NK (2016) Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7(4):4624\u20134631. \n                    https:\/\/doi.org\/10.18632\/oncotarget.6614","journal-title":"Oncotarget"},{"issue":"1","key":"3860_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/archopht.124.1.54","volume":"124","author":"E Weis","year":"2006","unstructured":"Weis E, Shah CP, Lajous M, Shields JA, Shields CL (2006) The association between host susceptibility factors and uveal melanoma\u2014a meta-analysis. Arch Ophthalmol 124(1):54\u201360. \n                    https:\/\/doi.org\/10.1001\/archopht.124.1.54","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"3860_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4103\/0301-4738.154373","volume":"63","author":"P Rishi","year":"2015","unstructured":"Rishi P, Koundanya VV, Shields CL (2015) Using risk factors for detection and prognostication of uveal melanoma. Indian J Ophthalmol 63(2):110\u2013116","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"3860_CR64","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2005.04.020","volume":"112","author":"CP Shah","year":"2005","unstructured":"Shah CP, Weis E, Lajous M, Shields JA, Shields CL (2005) Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology 112(9):1599\u20131607","journal-title":"Ophthalmology"},{"issue":"4","key":"3860_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ajo.2009.11.028","volume":"149","author":"MA Mainster","year":"2010","unstructured":"Mainster MA, Turner PL (2010) Ultraviolet-B phototoxicity and hypothetical photomelanomagenesis: intraocular and crystalline lens photoprotection. Am J Ophthalmol 149(4):543\u2013549","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3860_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13244-015-0443-8","volume":"7","author":"BS Purohit","year":"2016","unstructured":"Purohit BS, Vargas MI, Ailianou A, Merlini L, Poletti P-A, Platon A, Delattre BM, Rager O, Burkhardt K, Becker M (2016) Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging. Insights Imaging 7(1):43\u201368","journal-title":"Insights Imaging"},{"issue":"3","key":"3860_CR67","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/archopht.118.3.360","volume":"118","author":"CL Shields","year":"2000","unstructured":"Shields CL, Cater J, Shields JA, Singh AD, Santos MC, Carvalho C (2000) Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol 118(3):360\u2013364","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"3860_CR68","first-page":"1414","volume":"42","author":"T Makitie","year":"2001","unstructured":"Makitie T, Summanen P, Tarkkanen A, Kivela T (2001) Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42(7):1414\u20131421","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"3860_CR69","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/CMR.0b013e32833906e3","volume":"20","author":"P Pinzani","year":"2010","unstructured":"Pinzani P, Mazzini C, Salvianti F, Massi D, Grifoni R, Paoletti C, Ucci F, Molinara E, Orlando C, Pazzagli M, Neri B (2010) Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression. Melanoma Res 20(4):303\u2013310. \n                    https:\/\/doi.org\/10.1097\/CMR.0b013e32833906e3","journal-title":"Melanoma Res"},{"issue":"5","key":"3860_CR70","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1167\/iovs.09-4739","volume":"51","author":"M el Filali","year":"2010","unstructured":"el Filali M, Missotten GS, Maat W, Ly LV, Luyten GP, van der Velden PA, Jager MJ (2010) Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci 51(5):2329\u20132337. \n                    https:\/\/doi.org\/10.1167\/iovs.09-4739","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"3860_CR71","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/archopht.124.10.1428","volume":"124","author":"GS Missotten","year":"2006","unstructured":"Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, Jager MJ (2006) Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 124(10):1428\u20131434. \n                    https:\/\/doi.org\/10.1001\/archopht.124.10.1428","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"3860_CR72","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/02713680601161220","volume":"32","author":"K Mallikarjuna","year":"2007","unstructured":"Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S (2007) Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 32(3):281\u2013290. \n                    https:\/\/doi.org\/10.1080\/02713680601161220","journal-title":"Curr Eye Res"},{"issue":"1","key":"3860_CR73","first-page":"1","volume":"43","author":"C All-Ericsson","year":"2002","unstructured":"All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O (2002) Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 43(1):1\u20138","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3860_CR74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0161-6420(01)00902-2","volume":"109","author":"CL Shields","year":"2002","unstructured":"Shields CL, Shields JA, Perez N, Singh AD, Cater J (2002) Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 109(2):225\u2013234","journal-title":"Ophthalmology"},{"issue":"1","key":"3860_CR75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijrobp.2012.08.026","volume":"86","author":"Z Wang","year":"2013","unstructured":"Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, Murad MH (2013) Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 86(1):18\u201326. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2012.08.026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"3860_CR76","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1001\/archopht.120.12.1665","volume":"120","author":"E Gragoudas","year":"2002","unstructured":"Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM (2002) Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120(12):1665\u20131671","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"3860_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5114\/jcb.2016.57818","volume":"8","author":"M Naseripour","year":"2016","unstructured":"Naseripour M, Jaberi R, Sedaghat A, Azma Z, Nojomi M, Falavarjani KG, Nazari H (2016) Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachyther 8(1):66\u201373","journal-title":"J Contemp Brachyther"},{"issue":"1","key":"3860_CR78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3747\/co.23.2859","volume":"23","author":"E Weis","year":"2016","unstructured":"Weis E, Salopek TG, McKinnon JG, Larocque MP, Temple-Oberle C, Cheng T, McWhae J, Sloboda R, Shea-Budgell M (2016) Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol 23(1):57\u201364","journal-title":"Curr Oncol"},{"issue":"4","key":"3860_CR79","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/bjo.2009.162487","volume":"94","author":"NE Bechrakis","year":"2010","unstructured":"Bechrakis NE, Petousis V, Willerding G, Krause L, Wachtlin J, Stroux A, Foerster MH (2010) Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 94(4):460\u2013466. \n                    https:\/\/doi.org\/10.1136\/bjo.2009.162487","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"3860_CR80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/bjophthalmol-2015-307095","volume":"100","author":"GD Willerding","year":"2016","unstructured":"Willerding GD, Cordini D, Moser L, Krause L, Foerster MH, Bechrakis NE (2016) Neoadjuvant proton beam irradiation followed by transscleral resection of uveal melanoma in 106 cases. Br J Ophthalmol 100(4):463\u2013467. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307095","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3860_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","volume":"13","author":"ER Simpson","year":"2014","unstructured":"Simpson ER, Gallie B, Laperrierre N, Beiki-Ardakani A, Kivel\u00e4 T, Raivio V, Heikkonen J, Desjardins L, Dendale R, Mazal A, Bornfeld N, Sauerwein W, Fl\u00fcehs D, Brualla L, Honavar SG, Reddy VA, Suzuki S, Murakami N, Saakyan S, Valskiy V, Amiryan A, Seregard S, All-Eriksson C, Hjelmqvist L, Lundell G, Sinclair G, Lundell M, Damato B, Errington RD, Mayles P, Mayles H, Bergstrom C, Grossniklaus H, Crocker I, Butker E, Wilson M, Haik B, Geischen H, Patra P, Duker J, Mignano J, Rivard M, Finger PT, Semenova E, Choi W, Kalach NI (2014) The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 13(1):1\u201314. \n                    https:\/\/doi.org\/10.1016\/j.brachy.2013.11.008","journal-title":"Brachytherapy"},{"key":"3860_CR82","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/OPTH.S28863","volume":"7","author":"PR Pereira","year":"2013","unstructured":"Pereira PR, Odashiro AN, Lim L-A, Miyamoto C, Blanco PL, Odashiro M, Maloney S, De Souza DF, Burnier MN Jr (2013) Current and emerging treatment options for uveal melanoma. Clin Ophthalmol 7:1669\u20131682","journal-title":"Clin Ophthalmol"},{"key":"3860_CR83","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000351055","volume":"52","author":"S Seregard","year":"2013","unstructured":"Seregard S, Pelayes DE, Singh AD (2013) Radiation therapy: uveal tumors. Dev Ophthalmol 52:36\u201357. \n                    https:\/\/doi.org\/10.1159\/000351055","journal-title":"Dev Ophthalmol"},{"issue":"5","key":"3860_CR84","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0360-3016(97)00557-9","volume":"39","author":"IK Daftari","year":"1997","unstructured":"Daftari IK, Char DH, Verhey LJ, Castro JR, Petti PL, Meecham WJ, Kroll S, Blakely EA (1997) Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int J Radiat Oncol Biol Phys 39(5):997\u20131010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"3860_CR85","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ijrobp.2005.01.016","volume":"62","author":"B Damato","year":"2005","unstructured":"Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD (2005) Proton beam radiotherapy of choroidal melanoma: the Liverpool\u2013Clatterbridge experience. Int J Radiat Oncol Biol Phys 62(5):1405\u20131411. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2005.01.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3860_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/cco.2016.07.06","volume":"5","author":"KK Mishra","year":"2016","unstructured":"Mishra KK, Daftari IK (2016) Proton therapy for the management of uveal melanoma and other ocular tumors. Chin Clin Oncol 5(4):50\u201357","journal-title":"Chin Clin Oncol"},{"issue":"3","key":"3860_CR87","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.sjopt.2013.06.014","volume":"27","author":"B Damato","year":"2013","unstructured":"Damato B, Kacperek A, Errington D, Heimann H (2013) Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol 27(3):151\u2013157","journal-title":"Saudi J Ophthalmol"},{"issue":"9","key":"3860_CR88","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/eye.2015.109","volume":"29","author":"MJ Sikuade","year":"2015","unstructured":"Sikuade MJ, Salvi S, Rundle PA, Errington DG, Kacperek A, Rennie IG (2015) Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye (Lond) 29(9):1194\u20131198","journal-title":"Eye (Lond)"},{"issue":"2\u20133","key":"3860_CR89","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000098525","volume":"85","author":"AJ Fakiris","year":"2007","unstructured":"Fakiris AJ, Lo SS, Henderson MA, Witt TC, Worth RM, Danis RP, Des Rosiers PM, Timmerman RD (2007) Gamma-knife-based stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg 85(2\u20133):106\u2013112. \n                    https:\/\/doi.org\/10.1159\/000098525","journal-title":"Stereotact Funct Neurosurg"},{"issue":"8","key":"3860_CR90","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00417-016-3356-4","volume":"254","author":"I Seibel","year":"2016","unstructured":"Seibel I, Cordini D, Hager A, Riechardt AI, Rehak M, Boker A, Bohmer D, Heufelder J, Joussen AM (2016) Cataract development in patients treated with proton beam therapy for uveal melanoma. Graefes Arch Clin Exp Ophthalmol 254(8):1625\u20131630. \n                    https:\/\/doi.org\/10.1007\/s00417-016-3356-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3860_CR91","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/bjophthalmol-2013-304432","volume":"98","author":"P Rundle","year":"2014","unstructured":"Rundle P (2014) Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol 98(4):494\u2013497. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304432","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"3860_CR92","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1097\/IAE.10.1097\/IAE.0b013e31822c28ec","volume":"32","author":"WG Campbell","year":"2012","unstructured":"Campbell WG, Pejnovic TM (2012) Treatment of amelanotic choroidal melanoma with photodynamic therapy. Retina 32(7):1356\u20131362. \n                    https:\/\/doi.org\/10.1097\/IAE.10.1097\/IAE.0b013e31822c28ec","journal-title":"Retina"},{"key":"3860_CR93","doi-asserted-by":"publisher","first-page":"44564","DOI":"10.1038\/srep44564","volume":"7","author":"P Fagone","year":"2017","unstructured":"Fagone P, Caltabiano R, Russo A, Lupo G, Anfuso CD, Basile MS, Longo A, Nicoletti F, De Pasquale R, Libra M, Reibaldi M (2017) Identification of novel chemotherapeutic strategies for metastatic uveal melanoma. Sci Rep 7:44564\u201344574. \n                    https:\/\/doi.org\/10.1038\/srep44564","journal-title":"Sci Rep"},{"issue":"12","key":"3860_CR94","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","volume":"17","author":"A Schmittel","year":"2006","unstructured":"Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, Foerster MH, Thiel E, Keilholz U (2006) A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 17(12):1826\u20131829. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdl309","journal-title":"Ann Oncol"},{"key":"3860_CR95","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-1-4939-6481-9_17","volume":"1499","author":"M Kummer","year":"2017","unstructured":"Kummer M, Schuler-Thurner B (2017) Immunotherapy of uveal melanoma: vaccination against cancer. Methods Mol Biol 1499:273\u2013278. \n                    https:\/\/doi.org\/10.1007\/978-1-4939-6481-9_17","journal-title":"Methods Mol Biol"},{"key":"3860_CR96","unstructured":"Uveal melanoma (2016) National Institute of Health (\n                    https:\/\/clinicaltrials.gov\/\n                    \n                  )"},{"issue":"3","key":"3860_CR97","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kampgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D (2015) Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One 10(3):e0118564. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0118564","journal-title":"PLoS One"},{"issue":"suppl_8","key":"3860_CR98","doi-asserted-by":"publisher","first-page":"viii442","DOI":"10.1093\/annonc\/mdy289","volume":"29","author":"JM Piulats Rodriguez","year":"2018","unstructured":"Piulats Rodriguez JM, De La Cruz Merino L, Espinosa E, Alonso Carri\u00f3n L, Martin Algarra S, L\u00f3pez-Castro R, Curiel Garc\u00eda MT, Rodriguez Abreu D, Rullan Iriarte AJ, Berrocal Jaime A (2018) Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. Ann Oncol 29(suppl_8):viii442\u2013viii466. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy289","journal-title":"Ann Oncol"},{"key":"3860_CR99","doi-asserted-by":"publisher","unstructured":"Agarwala S, Ross M, Zager J, Shirai K, Essner R, Smithers B, Atkinson VG, Sarson D, Wachter E (2018) Interim results of a phase 1b\/2 study of PV-10 and anti-PD-1 in advanced melanoma. In: MR congress 2018 abstracts. \n                    https:\/\/doi.org\/10.1111\/pcmr.12738","DOI":"10.1111\/pcmr.12738"},{"issue":"15","key":"3860_CR100","doi-asserted-by":"crossref","first-page":"suppl. 9031","DOI":"10.1200\/jco.2013.31.15_suppl.9031","volume":"31","author":"JJ Sacco","year":"2013","unstructured":"Sacco JJ, Nathan PD, Danson S, Lorigan P, Nicholson S, Ottensmeier C, Corrie P, Steven N, Goodman A, Larkin JMG, Evans TRJ, Kumar S, Coupland SE, Silcocks P, Marshall E (2013) Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. J Clin Oncol 31(15):suppl. 9031","journal-title":"J Clin Oncol"},{"issue":"2","key":"3860_CR101","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2214\/AJR.14.14001","volume":"205","author":"CF Gonsalves","year":"2015","unstructured":"Gonsalves CF, Eschelman DJ, Thornburg B, Frangos A, Sato T (2015) Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea. AJR Am J Roentgenol 205(2):429\u2013433. \n                    https:\/\/doi.org\/10.2214\/AJR.14.14001","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"3860_CR102","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-0033-1333652","volume":"30","author":"DJ Eschelman","year":"2013","unstructured":"Eschelman DJ, Gonsalves CF, Sato T (2013) Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol 30(1):39\u201348","journal-title":"Semin Intervent Radiol"},{"issue":"2","key":"3860_CR103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.seminoncol.2010.03.014","volume":"37","author":"T Sato","year":"2010","unstructured":"Sato T (2010) Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 37(2):127\u2013138. \n                    https:\/\/doi.org\/10.1053\/j.seminoncol.2010.03.014","journal-title":"Semin Oncol"},{"issue":"2","key":"3860_CR104","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/annonc\/mdl158","volume":"18","author":"G Parmiani","year":"2007","unstructured":"Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18(2):226\u2013232. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdl158","journal-title":"Ann Oncol"},{"issue":"2","key":"3860_CR105","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2214\/AJR.10.4881","volume":"196","author":"CF Gonsalves","year":"2011","unstructured":"Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T (2011) Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 196(2):468\u2013473. \n                    https:\/\/doi.org\/10.2214\/AJR.10.4881","journal-title":"AJR Am J Roentgenol"},{"key":"3860_CR106","first-page":"52490","volume":"95","author":"I Ben-Shabat","year":"2015","unstructured":"Ben-Shabat I, Hansson C, Eilard MS, Cahlin C, Rizell M, Lindn\u00e9r P, Mattsson J, Bagge RO (2015) Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. J Vis Exp 95:52490","journal-title":"J Vis Exp"},{"key":"3860_CR107","first-page":"53795","volume":"113","author":"EM de Leede","year":"2016","unstructured":"de Leede EM, Burgmans MC, Martini CH, Tijl FGJ, van Erkel AR, Vuyk J, Kapiteijn E, Verhoef C, van de Velde CJH, Vahrmeijer AL (2016) Percutaneous hepatic perfusion (PHP) with melphalan as a treatment for unresectable metastases confined to the liver. J Vis Exp 113:53795","journal-title":"J Vis Exp"},{"issue":"6","key":"3860_CR108","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US (2017) Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol 18(6):792\u2013802. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6","journal-title":"Lancet Oncol"},{"issue":"14","key":"3860_CR109","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2217\/fon-2018-0116","volume":"14","author":"JJ Sacco","year":"2018","unstructured":"Sacco JJ, Kalirai H, Kenyani J, Figueiredo CR, Coulson JM, Coupland SE (2018) Recent breakthroughs in metastatic uveal melanoma: a cause for optimism? Future Oncol 14(14):1335\u20131338. \n                    https:\/\/doi.org\/10.2217\/fon-2018-0116","journal-title":"Future Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03860-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03860-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03860-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T23:29:14Z","timestamp":1589066954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03860-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03860-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,11]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors confirm that there is no conflict of interest with respect to the publication of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. We also confirm that no ethical issues are raised in this work. The research does not involve experiments with humans or with animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No inform consent for human participation is needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}